Novartis needs new launches to keep up momentum
A strong second quarter pushed Novartis’s stock up 5% this morning, but Kymriah continues to look weak, and the jury is still out on Zolgensma.
Back to the drawing board for Sumitomo’s deal-making
Yet another project brought in through business development fails, exposing Sumitomo’s limited pipeline.
Twilight of the stem cell transplant adjuncts?
The ripples of Molmed’s pivotal study failure could stretch beyond the company’s Zalmoxis product.
Which direction for Turning Point?
Turning Point is heading into a highly competitive lung cancer niche with its lead project, which still has much to prove.
Affimed turns its back on T-cell recruitment
The German group’s decision to switch focus to innate immunity had been on the cards since a deal with Roche last August.
Exact falls on Guardant’s liquid biopsy plans
The mere possibility of Guardant horning in on colorectal cancer has spooked Exact’s investors.
Lundbeck leaps into the Tourette’s pipeline
By taking out Abide Therapeutics, Lundbeck has bought one of very few clinical-stage Tourette’s syndrome candidates.
Pressure on Abbvie's pipeline grows
Abbvie will need more than Skyrizi and upadacitinib to fill a Humira-shaped hole, and there are a few early-stage candidates it reckons could fit the bill.
Novartis and Biogen face spinal muscular atrophy reckoning
The upcoming American Academy of Neurology meeting could provide clues on how the market will shake out.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.